Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Palatability of Lenvatinib Suspension vs Capsule
NCT02792829Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lenvatinib in thyroid cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and 1 more (3 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve From Zero to Infinity and 4 more. Started Aug 2014; status: completed.
02
Drugs
lenvatinib
03
Conditions
thyroid cancerrenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)endometrial carcinoma
Beyond the preview
Go deeper on NCT02792829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792829.